Abstract
Novel drugs are continuing to bring improved health benefits to an increasing number of patients. However, the costs of delivering these new treatments continue to grow year by year. Pharmaceutical companies often justify these increasing reimbursement costs based on the persistently high attrition rate of promising new compounds failing through the lengthy drug discovery process.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
